Compare Cintas Corporation (CTAS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Zoetis Inc — how do they compare? Cintas Corporation trades at $193.95 (market cap $73.76B), while Zoetis Inc trades at $75.57 (market cap $31.05B). The key difference: Cintas Corporation is far larger — about 2.4× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.86%). Which is the better fit depends on your goals.
| CTAS | ZTS | |
|---|---|---|
Market Cap | $73.76B | $31.05B |
Sector | Industrials | Health |
52-Week High | $226.27 | $156.76 |
52-Week Low | $163.55 | $71.91 |
Enterprise Value | $76.49B | $38.35B |
Dividend Yield | 0.98% | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $183.75, up 2.29% on the day, with a bullish technical outlook supported by moving averages and strong support at $182. The company shows robust fundamentals with revenue growing to $10.34B in 2025 and net income reaching $1.81B, though valuation ratios like P/E of 38.77 appear elevated. Recent news highlights upcoming Q4 earnings and continued recognition as a top employer.
The stock offers a compelling growth story with consistent earnings beats and a 43-year dividend growth track record, but faces risks from high valuation and economic sensitivity. Analyst consensus is mixed with a $212.50 price target, suggesting moderate upside potential if execution remains strong amid competitive pressures.
Zoetis (ZTS) trades at $75.39, down 0.22% with bearish technical signals and mixed sentiment. The company maintains strong fundamentals with $9.47B revenue, 28.03% net margin, and robust profitability metrics (ROE 67.75%, ROA 18.27%). Recent Q1 2026 earnings missed expectations, while multiple law firms have filed class action lawsuits alleging securities violations between January 2025 and May 2026.
Despite strong financials and analyst consensus price target of $101.43 (34.5% upside), ZTS faces significant legal risks and technical weakness. The stock presents a value opportunity for long-term investors willing to navigate near-term volatility, though the class action lawsuits create substantial uncertainty for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
